Clinical Trials Directory

Trials / Completed

CompletedNCT01413542

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Vanderbilt University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

Detailed description

To test the hypothesis that DPPIV inhibition with sitagliptin potentiates the vasodilator response to substance P in the presence of ACE inhibition with enalaprilat and to BNP and GLP-1 even in the presence of ACE inhibition. The aim promises to provide important new data regarding the mechanism of action of DPPIV inhibitors and interactive effects of these two drug classes used in a growing population of diabetic patients.

Conditions

Interventions

TypeNameDescription
DRUGSitagliptin (DPP4 inhibitor)Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
DRUGSubstance P,Substance P intra-brachial artery (2,4,8 pmol/min)
DRUGbradykininbradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
DRUGenalaprilat (ACE inhibitor)intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
DRUGGlucagon-like peptide 1intra-brachial artery (0.45-3.60 pmol/min)
DRUGbrain natriuretic peptideIntra-brachial artery (0.90, 1.80 and 3.6 pmol/min)

Timeline

Start date
2011-11-01
Primary completion
2013-07-01
Completion
2014-07-01
First posted
2011-08-10
Last updated
2015-11-04
Results posted
2015-11-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01413542. Inclusion in this directory is not an endorsement.